Abstract:Ubiquitin-specific peptidase 7 (USP7) is a deubiquitinating enzyme that mediates the stability and activity of numerous proteins. At basal expression levels, USP7 stabilizes p53 protein, even in the presence of excess MDM2. However, its overexpression leads to the deubiquitination of MDM2 at a rate faster than p53, leading to p53 degradation and pro-tumorigenic roles. Consequently, it is an attractive target for anticancer drug discovery via the modulation of its allosteric site from which the protein is activated. In this study, molecular modeling techniques and cheminformatics approaches were employed to unravel the potential of eighty compounds to serve as its allosteric site modulators. The compounds were initially subjected to virtual screening. Subsequently, the binding free energies of the top four compounds with the highest binding affinities were calculated, and their drug-likeness, and pharmacokinetic and toxicity profiles were evaluated. Ultimately, the complexes of the protein and hit compounds were subjected to a 100 nanoseconds (ns) molecular dynamics simulation. The results of the study revealed eight compounds from the compound library with docking scores ranging from - 7.491 to -11.43 kcal/mol, compared to P217564, which exhibited a docking score of -5.671 kcal/mol. The top four compounds with the highest affinities possessed drug-like properties, and good pharmacokinetic and toxicity profiles, and their predicted inhibitory potentials showed they will be effective at minimal concentration. Also, molecular dynamics simulation confirmed the stability of the protein-ligand complexes. Conclusively, the compounds identified in this study are worthy of further evaluation for the development of allosteric site modulators of USP7.

Validation of Catalytic Site Residues of Ubiquitin Specific Protease 2 (USP2) by Molecular Dynamic Simulation and Novel Kinetics Assay for Rational Drug Design

Cheminformatics-aided discovery of potential allosteric site modulators of ubiquitin-specific protease 7

Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.

Development of a highly reliable assay for ubiquitin-specific protease 2 inhibitors.

Dynamic regions allosterically connect the USP14 active site with the proteasome interaction surface

Elastic network models and molecular dynamic simulations reveal the molecular basis of allosteric regulation in ubiquitin-specific protease 7 (USP7)

Structure-based Virtual Screening of Novel USP5 Inhibitors Targeting the Zinc Finger Ubiquitin-Binding Domain

Variety in the USP deubiquitinase catalytic mechanism

Development of a robust HTRF assay with USP7 full length protein expressed in E. coli prokaryotic system for the identification of USP7 inhibitors

In silico screening and computational evaluation of novel promising USP14 inhibitors targeting the palm-thumb pocket

Discovery of Ubiquitin-Specific Protease 7 (USP7) Inhibitors with Novel Scaffold Structures by Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation

Mechanistic Insights into Dynamic Mutual Regulation of USP14 and Proteasome

Discovery of Novel USP8 Inhibitors Via Ubiquitin-Rho-110 Fluorometric Assay Based High Throughput Screening.

Stereo-selectivity of enantiomeric inhibitors to ubiquitin-specific protease 7 (USP7) dissected by molecular docking, molecular dynamics simulations, and binding free energy calculations

Structural Dynamics of the Ubiquitin Specific Protease USP30 in Complex with a Cyanopyrrolidine-Containing Covalent Inhibitor

Ubiquitin Specific Protease 2: Structure% Isoforms% Cellular Function% Related Diseases and Its Inhibitors

Structural Dynamics Analysis of USP14 Activation by AKT-Mediated Phosphorylation

Identification of new leads against ubiquitin specific protease-7 (USP7): a step towards the potential treatment of cancers

USP7: Target Validation and Drug Discovery for Cancer Therapy

Revealing USP7 Deubiquitinase Substrate Specificity by Unbiased Synthesis of Ubiquitin Tagged SUMO2

Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors